Skip to content

Advertisement

BMC Cancer

Medical and radiation oncology

Section edited by Dirk Vordermark

This section focuses on clinical research that impacts on the treatment of cancer using systemic chemotherapy, targeted therapy, and radiation.

Previous Page Page 2 of 23 Next Page
  1. Content type: Research article

    Regorafenib is a multi-kinase inhibitor, which was shown to be effective for patients with metastatic colorectal cancer refractory to standard therapies. However, its patterns of response has not yet been full...

    Authors: Yukinori Ozaki, Junichi Shindoh, Wataru Gonoi, Yujiro Nishioka, Chihiro Kondoh, Yuko Tanabe, Shuichiro Matoba, Hiroya Kuroyanagi, Masaji Hashimoto and Toshimi Takano

    Citation: BMC Cancer 2018 18:138

    Published on:

  2. Content type: Study protocol

    Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or re...

    Authors: Masahiro Sekimizu, Akihiro Iguchi, Tetsuya Mori, Yuhki Koga, Akiko Kada, Akiko M. Saito and Keizo Horibe

    Citation: BMC Cancer 2018 18:122

    Published on:

  3. Content type: Research article

    To evaluate the prognostic significance of pretreatment quality of life for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.

    Authors: Shan-Shan Guo, Wen Hu, Qiu-Yan Chen, Jian-Mei Li, Shi-Heng Zhu, Yan He, Jia-Wen Li, Le Xia, Lu Ji, Cui-Ying Lin, Li-Ting Liu, Lin-Quan Tang, Ling Guo, Hao-Yuan Mo, Chong Zhao, Xiang Guo…

    Citation: BMC Cancer 2018 18:114

    Published on:

  4. Content type: Research article

    Ramucirumab has recently proved to be effective for advanced or recurrent gastric cancer (AGC). Ascites and peritoneal metastasis are among the most common complications of AGC. However, there are few data on ...

    Authors: Hiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, Shota Fukuoka, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Atsushi Ohtsu, Takayuki Yoshino, Toshihiko Doi and Kohei Shitara

    Citation: BMC Cancer 2018 18:120

    Published on:

  5. Content type: Research article

    Neoadjuvant chemotherapy (NAC) is extensively used in the treatment of patients with gastric cancer (GC), particularly in high risk, advanced gastric cancer. Previous trials testing the efficacy of NAC have re...

    Authors: Zhi-Feng Miao, Xing-Yu Liu, Zhen-Ning Wang, Ting-Ting Zhao, Ying-Ying Xu, Yong-Xi Song, Jin-Yu Huang, Hao Xu and Hui-Mian Xu

    Citation: BMC Cancer 2018 18:118

    Published on:

  6. Content type: Research article

    Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is l...

    Authors: Edurne Arriola, Ramón García Gómez, Pilar Diz, Margarita Majem, Maite Martínez Aguillo, Javier Valdivia, Alfredo Paredes, José Miguel Sánchez-Torres, Sergio Peralta Muñoz, Isidoro Barneto, Vanesa Gutierrez, Jesús Manuel Andrade Santiago, Francisco Aparisi, Dolores Isla, Santiago Ponce, David Vicente Baz…

    Citation: BMC Cancer 2018 18:106

    Published on:

  7. Content type: Research article

    Galectin-1, a radioresistance marker, was found in our previous study to be a prognostic factor for cervical cancer. The aim of current study is to determine the prognostic significance of the galectin-1 expre...

    Authors: Shang-Yu Chou, Shao-Lun Yen, Chao-Cheng Huang and Eng-Yen Huang

    Citation: BMC Cancer 2018 18:105

    Published on:

  8. Content type: Research article

    The prognosis of hepatocellular carcinoma with portal vein tumor thrombus remains extremely poor. This pilot study aimed to evaluate the technical feasibility, effectiveness and safety of transcatheter chemoem...

    Authors: Biao Yang, Chun-Lin Li, Wen-hao Guo, Tian-qiang Qin, He Jiao, Ze-jun Fei, Xuan Zhou, Lin-jia Duan and Zheng-yin Liao

    Citation: BMC Cancer 2018 18:101

    Published on:

  9. Content type: Study protocol

    Few data are available regarding the treatment of metastatic colorectal cancer elderly patients with anti-EGFR agents in combination with chemotherapy. FOLFOX plus panitumumab is a standard first-line option for

    Authors: Francesca Battaglin, Marta Schirripa, Federica Buggin, Filippo Pietrantonio, Federica Morano, Giorgia Boscolo, Giuseppe Tonini, Eufemia Stefania Lutrino, Jessica Lucchetti, Lisa Salvatore, Alessandro Passardi, Chiara Cremolini, Ermenegildo Arnoldi, Mario Scartozzi, Nicoletta Pella, Luca Boni…

    Citation: BMC Cancer 2018 18:98

    Published on:

  10. Content type: Case report

    Herein, we report a complete response after whole brain radiotherapy (WBRT) and concomitant T-DM1 in a patient with HER2-positive metastatic breast cancer (MBC) and extensive brain and leptomeningeal involvement.

    Authors: Giuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, Silvia Schifano, Giampiero Mastroeni, Anna Santacaterina and Vincenzo Adamo

    Citation: BMC Cancer 2018 18:97

    Published on:

  11. Content type: Case report

    Immune checkpoint blockade is developed as standard treatment for non-small cell lung cancer. However immune-related adverse events (irAE) have still unknown complications. Here, we report a patient with lung ...

    Authors: Yoshitsugu Narumi, Ryohei Yoshida, Yoshinori Minami, Yasushi Yamamoto, Shiori Takeguchi, Kohei Kano, Kae Takahashi, Tsukasa Saito, Jun Sawada, Hiroya Terui, Takayuki Katayama, Takaaki Sasaki and Yoshinobu Ohsaki

    Citation: BMC Cancer 2018 18:95

    Published on:

  12. Content type: Case report

    Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal cell carcinoma and soft tissue sarcoma. Liver toxicity is a common side effect for this class of agents. The current opinion is th...

    Authors: Arie J. Verschoor, Fabiënne A. R. M. Warmerdam, Tjalling Bosse, Judith V. M. G. Bovée and Hans Gelderblom

    Citation: BMC Cancer 2018 18:92

    Published on:

  13. Content type: Research article

    To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) pat...

    Authors: Minzhi Xing, Nima Kokabi, Juan C. Camacho and Hyun S. Kim

    Citation: BMC Cancer 2018 18:75

    Published on:

  14. Content type: Research article

    Biliary tract cancer (BTC) is a dismal disease, even after curative intent surgery. We conducted this prospective, non-randomized phase II study to evaluate the feasibility and efficacy of cisplatin and gemcit...

    Authors: Alexander R. Siebenhüner, Heike Seifert, Helga Bachmann, Burkhardt Seifert, Thomas Winder, Jonas Feilchenfeldt, Stefan Breitenstein, Pierre-Alain Clavien, Roger Stupp, Alexander Knuth, Bernhard Pestalozzi and Panagiotis Samaras

    Citation: BMC Cancer 2018 18:72

    Published on:

  15. Content type: Study protocol

    Systemic treatment for advanced cancer offers uncertain and sometimes little benefit while the burden can be high. Hence, treatment decisions require Shared Decision Making (SDM). The CHOICE trial examines the...

    Authors: I. Henselmans, E. M. A. Smets, J. C. J. M. de Haes, M. G. W. Dijkgraaf, F. Y. de Vos and H. W. M. van Laarhoven

    Citation: BMC Cancer 2018 18:55

    Published on:

  16. Content type: Research article

    The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly discussed at international consensus meetings, but is compromised by the lack of solid evidence from clini...

    Authors: Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher, Nicolas Schleif, Ursula Cirrincione, Axel Hinke and Gabriele Feisel-Schwickardi

    Citation: BMC Cancer 2018 18:51

    Published on:

  17. Content type: Study protocol

    Oxaliplatin + S-1 is a recognized treatment regimen in Japan, but there are no Japanese clinical data on an oxaliplatin dose of 130 mg/m2. The current research involves a single-arm, prospective, phase II clinica...

    Authors: Hiroshi Saeki, Yasunori Emi, Eiji Oki, Shoji Tokunaga, Yoshihiro Kakeji, Yoshito Akagi, Hideo Baba, Eishi Baba and Yoshihiko Maehara

    Citation: BMC Cancer 2018 18:57

    Published on:

  18. Content type: Research article

    The 21-gene recurrence score (RS) assay determines the benefit of adding chemotherapy to endocrine therapy for patients with early stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. The RS ri...

    Authors: Gulisa Turashvili, Edi Brogi, Monica Morrow, Maura Dickler, Larry Norton, Clifford Hudis and Hannah Y. Wen

    Citation: BMC Cancer 2018 18:42

    Published on:

  19. Content type: Study protocol

    Glioblastoma relapses in the vast majority of cases within 1 year. Maximum safe resection of the recurrent glioblastoma can be offered in some cases. Re-irradiation has been established for the treatment of re...

    Authors: Christoph Straube, Hagen Scherb, Jens Gempt, Jan Kirschke, Claus Zimmer, Friederike Schmidt-Graf, Bernhard Meyer and Stephanie E. Combs

    Citation: BMC Cancer 2018 18:15

    Published on:

  20. Content type: Research article

    To compare the efficacy of crizotinib, pemetrexed and other chemotherapy regimens as a first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in real...

    Authors: Jianya Zhou, Jing Zheng, Xiaochen Zhang, Jing Zhao, Yanping Zhu, Qian Shen, Yuehong Wang, Ke Sun, Zeying Zhang, Zhijie Pan, Yihong Shen and Jianying Zhou

    Citation: BMC Cancer 2018 18:10

    Published on:

Previous Page Page 2 of 23 Next Page